Stock Details
TAK is Takeda Pharmaceutical Company Limited's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 13.67$. Average daily volumn in 3 months 2.58M. Market cap 40.39B



Stock symbol : TAK. Exchange : NYSE. Currency : USD
Lastest price : 13.14$. Total volume : 3.91M. Market state POST
Click reload if you want to check the lastest price on market!!!

Takeda Pharmaceutical Company Limited (TAK)
Last Price
13.14$
Change
0.02
Volume
3.91M

Previous Close13.12
Open13.04
Day Range13.04-13.19
Bid12.80 x 34.1k
Ask13.23 x 3.2k
Volume3.91M
Average Volume2.58M
Market Cap40.39B
Beta0.75
52 Week Range12.75-15.36
Trailing P/E29.86
Foward P/E6.64
Dividend (Yield %)5.40%
Ex-Dividend Date2022-03-30



Financial Details


According to Takeda Pharmaceutical Company Limited's financial reports the company's revenue in 2022 were 3.57T an increase(0%) over the years 2021 revenue that were of 3.2T. In 2022 the company's total earnings were 230.06B while total earnings in 2021 were 376B(-38.83%).


Loading ...



Organization

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynov... ate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Market Cap:
40.39B
Revenue:
3.57T
Total Assets:
13.18T
Total Cash:
849.7B


News about "Takeda Pharmaceutical Company Limited"

Takeda Pharmaceutical Company Limited (TAK)

Source from : Yahoo Finance - 3 days ago

While major pharmaceutical companies have always been derided for considering profits over the well-being [โ€ฆ] The FDA has accepted Takeda Pharmaceutical Co Ltd's (NYSE: TAK) supplemental ...See details»


takeda-pharmaceutical-company-limited-nysetak-shares-acquired-by-private-advisor-group-llc-image

Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Acquired by Private Advisor Group LLC

Source from : Defense World - 9 days ago

Private Advisor Group LLC raised its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK โ€“ Get Rating) by 26.3% during the second quarter, according to the company in its most recent ...See details»


Takeda Pharmaceutical Co Ltd

Source from : Reuters - 2 years ago

AM UTCQ2 2023 Takeda Pharmaceutical Co Ltd Earnings Release 02 Feb 2023 / 6:00 AM UTCQ3 2023 Takeda Pharmaceutical Co Ltd Earnings Release ...See details»


veriti-management-llc-increases-position-in-takeda-pharmaceutical-company-limited-nysetak-image

Veriti Management LLC Increases Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Source from : Defense World - 9 days ago

Veriti Management LLC increased its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK โ€“ Get Rating) by 41.5% during the second quarter, according to the company in its most recent ...See details»


Takeda Pharmaceutical Company Limited (TAK): Odds are Looking Good after Recent Activity

Source from : investchronicle - 9 days ago

Letโ€™s start up with the current stock price of Takeda Pharmaceutical Company Limited (TAK), which is $13.02 to be very precise. The Stock rose vividly during the last session to $12.9221 after opening ...See details»


6Short Volatility Alert: Takeda Pharmaceutical Company Limited

Source from : Benzinga.com - 9 days ago

On Tuesday, shares of Takeda Pharmaceutical Company Limited (TAK) experienced volatile short activity. After the activity, the stock price went down -0.08% to $12.80. The overall sentiment for ILUS ...See details»


Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Source from : Nasdaq - 2 years ago

Please note that the dividend history might include the companyโ€™s preferred securities as well. Price/Earnings Ratio is a widely used stock evaluation measure. For a security, the Price ...See details»


takeda-pharmas-india-operations-become-united-nations-global-compact-signatory-image

Takeda Pharma's India operations become United Nations Global Compact signatory

Source from : Daily - 10 days ago

Takeda Pharmaceutical Company Limited has announced that its India operations have become a signatory of the United Nations Global Compact (UNGC), the largest sustainability ...See details»


Takeda Pharmaceuticals Company: 3D Consultations for Takeda

Source from : Warc - 2 month ago

Takeda knew from sales and primary research that there is a delay in prescribing biologics as a whole to Irritable Bowel Disease (IBD) patients โ€“ and, of course, within this sits their own unique ...See details»


japanese-ambassador-to-ireland-celebrates-25-years-of-takeda-pharma-in-bray-image

Japanese Ambassador to Ireland celebrates 25 years of Takeda Pharma in Bray

Source from : Independent.ie - 16 hours ago

Takeda Pharmaceuticals celebrated 25 years in Ireland recently at its Bray HQ at Bray Business Park. A gathering of approximately 1,000 people, comprising dignitaries, company leaders, development ...See details»


Enzyme Replacement Therapy Market See Huge Growth for New Normal | Takeda Pharmaceutical Company Limited, Sanofi S.A., AbbVie Inc.

Source from : Digital Journal - 21 days ago

New Jersey (United States) The Enzyme Replacement Therapy Market research report provides all the information related to the industry. It gives the markets outlook by giving authentic data to its ...See details»


Hereditary Angioedema Market to Exhibit Skyrocketing Expansion During 2022-2028 | CSL Behring, Takeda Pharmaceutical Company Limited., Pharming

Source from : Digital Journal - 1 month ago

Find the complete Hereditary Angioedema Market analysis segmented by companies, region, type and applications in the report. The research focuses on the drivers and restraints that impact market ...See details»


Heidelberg Pharma Announces Conclusion of Licenseโ€ฆ

Source from : PharmiWeb - 28 days ago

Ladenburg, Germany, 9 September 2022 โ€“ Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH and Takeda signed a license ... an oncology specialist and ...See details»


Takeda Pharmaceutical Company Limited (TAK)

Source from : Yahoo Finance - 2 days ago

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...See details»